Top Stories
Top Stories
Biotech and Pharma

Biogen to buy Nightstar Therapeutics in a $800 million cash deal

Key Points
  • Biogen said it will buy Nightstar Therapeutics for about $800 million in cash.
  • Biogen is looking to tap into a potentially lucrative gene therapy market.
  • London-based gene therapy company Nightstar is focused on adeno-associated virus treatments for inherited retinal disorders.
Employees at Biogen in Cambridge, Mass.
Suzanne Kreiter | The Boston Globe | Getty Images

Biogen said on Monday it will buy Nightstar Therapeutics for about $800 million in cash as the company looks to tap into a potentially lucrative gene therapy market.

Biogen's offer of $25.50 per share, represents a premium of 68 percent to Nightstar's Friday close of $15.16.

Gene therapy, an emerging field of biotechnology, uses specially engineered viruses, or viral vectors, to deliver genetic material into defective cells, in hopes of improving or potentially even curing an inherited condition.

London-based gene therapy company Nightstar is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.

"Ophthalmology is an emerging growth area for Biogen," said Michel Vounatsos, Biogen's chief executive officer. "Nightstar would accelerate our entry into ophthalmology by contributing two mid- to late-stage gene therapy assets."

Biogen said it plans to fund the acquisition through available cash.

Last week, Sarepta Therapeutics Inc beefed up its gene therapy portfolio through the purchase of its partner Myonexus Therapeutics, while Swiss drugmaker Roche said it was buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion.

Goldman, Sachs is acting as financial adviser to Biogen and Centerview Partners was Nightstar's financial adviser.

Next Article
Key Points
  • Bristol-Myers Squibb is meeting with shareholders in Boston and New York to calm worried investors.
  • Its $74 billion purchase of drugmaker Celgene is at risk of being derailed.
  • Hedge funds Wellington Management and Starboard Value are publicly opposing the deal.